fda approval of tirzepatide for weight loss is approved Semaglutide vs. Tirzepatide: Which Treatment Right You? Choosing between FDA approves weight-loss drug Zepbound

The GLP-1 biosimilars market is primarily driven by the rapidly increasing global prevalence of type 2 diabetes and obesity, rising demand for affordable biologic therapies, and the impending patent expirations of major originator GLP-1 drugs such as semaglutide and dulaglutide

What they found: In normal obese mice: AOD-9604 reduced body fat by 21 % vs placebo, hGH by 24 % The AOD-9604 effect was fully dependent on the 3-adrenergic receptor , in knock-out mice no effect The hGH effect was partly independent of 3-AR , in knock-out mice there was still ~10 % fat reduction AOD-9604 did not raise IGF-1 (control level), whereas hGH raised IGF-1 by 80 % No changes in growth, organ weights (except adipose tissue), fasting insulin Why it matters: The study provided the mechanistic basis for AOD-9604 and confirmed the key business hypothesis: it is possible to separate the lipolytic effect of GH from its growth effect

H.ClevelandD

If you feel sluggish or tired, it might be because your body isnt getting enough B12

Brain Sciences , 7

These developments underscore the expanding arsenal of diabetes drugs available to clinicians